Vascular endothelial growth factor induced functional and morphologic signs of endothelial dysfunction in isolated arteries from normal pregnant women

2003 ◽  
Vol 188 (1) ◽  
pp. 168-176 ◽  
Author(s):  
Eimantas Svedas ◽  
Khalid B. Islam ◽  
Henry Nisell ◽  
Karolina R. Kublickiene
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Endothelial Dysfunction ◽  
Pregnant Women ◽  
Vascular Endothelial ◽  
Isolated Arteries ◽  
Endothelial Growth Factor

High Levels of Urinary Vascular Endothelial Growth Factor in Women with Severe Preeclampsia

2004 ◽  
Vol 19 (1) ◽  
pp. 72-75 ◽  
Author(s):  
E.M. Roes ◽  
E.A.P. Steegers ◽  
C.M.G. Thomas ◽  
A. Geurts-Moespot ◽  
M.T.M. Raijmakers ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Endothelial Dysfunction ◽  
Pregnant Women ◽  
Systemic Circulation ◽  
Severe Preeclampsia ◽  
Vascular Endothelial ◽  
Elevated Plasma ◽  
Endothelial Growth Factor ◽  
Placental Ischemia

Elevated plasma VEGF concentrations in preeclampsia are associated with local placental ischemia and endothelial dysfunction. We investigated the urinary VEGF excretion in women with severe preeclampsia (n=37) and its relation with proteinuria compared to that in healthy pregnant (n=32) and non-pregnant women (n=30). In women with severe preeclampsia VEGF levels were 54.0 (19.9–192.4) ng/mmol creatinine, significantly (p<0.0001) higher than levels in pregnant controls (28.2 (6.7–63.0) ng/mmol creatinine) and non-pregnant controls (29.5 (10.1–59.1) ng/mmol creatinine). Proteinuria was not significantly correlated with urinary VEGF levels. In conclusion, high urinary VEGF concentrations in severe preeclampsia might reflect increased renal production of VEGF rather than elevated VEGF levels in the systemic circulation.

Early predictors of placental dysfunction

2016 ◽  
pp. 25-28
Author(s):  
J.M. Melnik ◽  
◽  
A.A. Shlyahtina ◽  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pregnant Women ◽  
Umbilical Artery ◽  
Placental Growth Factor ◽  
Vascular Endothelial ◽  
Endothelin 1 ◽  
Placental Dysfunction ◽  
Early Predictors ◽  
Endothelial Growth Factor

The article presents the predictors of placental dysfunction on the early stage of pregnancy. The objective: the search for prognostic markers and criteria for the occurrence of placental insufficiency in the early stages of the gestational process to optimize the pregnancy and labor with improved perinatal outcomes. Patients and methods. To solve this goal in the period from 2013 to 2015 were conducted a comprehensive survey of 334 pregnant women, which depending on the peculiarities of pregnancy and childbirth were divided into groups. The control group consisted of 236 pregnant women with uncomplicated gestational period, no morphological signs of placental dysfunction. The study group included 98 patients with a complicated pregnancy who had revealed violations of the fetal-placental relations, which was confirmed by morphological examination of the placenta in the postpartum period. Results. It was found that pregnant women with placental insufficiency in the first trimester of pregnancy have higher levels of interleukin-1B (IL-1v) and interleukin-3 (IL-3) in comparison with physiological pregnancy, as well as there is a direct significant correlation between IL-1v and pulsative index (PI) in the spiral (r=0.84) and uterine artery (r=0.77), and the inverse correlation between the level of IL-3 and PI in the terminal branches of the umbilical artery (r=-0.69). Verified an inverse relationship between the concentration of endothelin-1, the level of vascular endothelial growth factor (r=-0.87) and placental growth factor (r=-0.73), and also a direct link between the content of endothelin-1 and PI in spiral arteries (r=0.89), uterine artery (r=0.83) and the terminal branches of the umbilical artery (r=0.79). Conclusion. Thus, it is proven that early predictors of placental dysfunction can be considered the concentration of endothelin-1, vascular endothelial growth factor, placental growth factor, interleukin-1, interleukin-3, and the indices of pulsative index. Key words: placental dysfunction, predictors, endothelin-1, vascular endothelial growth factor, placental growth factor, interleukin, pulsative index.

Effects of Hypocrellin A on Expression of Vascular Endothelial Growth Factor and Endothelin-1 in Human Umbilical Endothelial Cells

2007 ◽  
Vol 35 (04) ◽  
pp. 713-723 ◽  
Author(s):  
Lei Dang ◽  
J. Paul Seale ◽  
Xianqin Qu
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Endothelial Cells ◽  
Growth Factor ◽  
Endothelial Dysfunction ◽  
Protein Expression ◽  
Vascular Endothelial ◽  
Naturally Occurring ◽  
Hypocrellin A ◽  
Endothelial Growth Factor ◽  
Vegf Protein

Increased endothelin-1 (ET-1), vascular endothelial growth factor (VEGF) and activation of protein kinase C (PKC) are co-contributors to endothelial hyperpermeability in diabetes. Several lines of evidence have suggested a hypothesis that activation of specific PKC isoforms are the causative factor in ET-1 and VEGF mediated endothelial dysfunction. In the present study, we tested this hypothesis with hypocrellin A, a naturally occurring PKC inhibitor from a Chinese plant. Human umbilical vein endothelial cells (HUVECs) were incubated with 20 mM glucose in both the presence and absence of hypocrellin A, after which, the protein expression and release of VEGF and mRNA expression and release of ET-1 were measured. VEGF and ET-1 were released into the medium and expressions of VEGF protein and ET-1 mRNA were significantly increased in HUVECs incubated with 20 mM glucose. Hypocrellin A (150 nM) significantly decreased VEGF release (117 ± 3 vs. 180 ± 11 pg/mg, p < 0.05) and VEGF protein expression (from 130 ± 14% to 88 ± 18.5%, p < 0.05). ET-1 release was also reduced in hypocrellin A treated HUVECs (63.3 ± 9.9 vs. 75.2 ± 12.6 ng/mg). Hypocrellin A significantly reversed the effect of high glucose on ET-1 mRNA expression ( p < 0.05). The results revealed that PKC activation plays a pivotal role in VEGF and ET-1 mediated endothelial permeability. The naturally occurring compound hypocrellin A may be a potentially novel treatment for endothelial dysfunction in diabetes.

scholarly journals A study of vascular endothelial growth factor in the cord blood of pre-eclamptics and healthy pregnant women

2017 ◽  
Vol 8 (1) ◽  
pp. 21-25
Author(s):  
Anita Rawat ◽  
Anil Kumar Gangwar ◽  
Archana Ghildiyal ◽  
Neena Srivastava ◽  
Sunita Tiwari ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cord Blood ◽  
Pregnant Women ◽  
Assay Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Vascular Endothelial ◽  
Cord Serum ◽  
Endothelial Growth Factor

Background: Pre-eclampsia(PE) is  the  most  frequently encountered  medical  complication  during  pregnancy. In developing countries PE   is a principal cause of maternal mortality. A disturbance  in  the  angiogenic/antiangiogenic  factors  and  in  the  hypoxia/placental re-oxygenation  process,  seems  to  activate a maternal  endothelial  dysfunction.Aims and Objective: To estimate Vascular Endothelial Growth Factor ( VEGF )  level  in the cord blood of healthy and Preeclamptic ( PEc ) pregnant women and to associate this with Preeclamptic pregnancy.Material and Methods: A case-control study ofUmbilical cord serum VEGF levels from women with uncomplicated pregnancies (control group, n=60) and pregnancies complicated by Pre-eclampsia (n=40). VEGF in the cord serum was estimated by SANDWICH Enzyme Linked Immunosorbent Assay method by using ELISA Kit and then compared between the two groups.Results: The mean VEGF concentrations in the women who had pre-eclampsia  (578.62±468.3)  were lower than in the control group( 625.75±533.1) , but the difference was not statistically significant ( p= 0.8548).  Conclusion VEGF plays a key role in the instability between endothelial dysfunction and angiogenesis that occurs during Preeclampsia.  VEGF levels might be a useful tool for the early diagnosis of Pre-eclampsia.Asian Journal of Medical Sciences Vol.8(1) 2017 21-25

scholarly journals The diagnostic Value of Vascular Endothelial Growth Factor in Women with Growth-Restricted Fetuses

Doctor Ru ◽  
2020 ◽  
Vol 19 (8) ◽  
pp. 44-48
Author(s):  
I.F. Fatkullin ◽  
◽  
N.R. Akhmadeev ◽  
E.V. Ulyanina ◽  
L.Kh. Islamova ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pregnant Women ◽  
Fetal Growth ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Vascular Endothelial ◽  
Group I ◽  
Low Weight ◽  
Endothelial Growth Factor

Study Objective: To assess delivery outcomes in women with slow fetal growth (ICD-10 code P05) and study serum levels of vascular endothelial growth factor (VEGF) and its diagnostic value in patients with growth-restricted fetuses that have constitutional low weight, in order to choose an approach to pregnancy management. Study Design: This was a prospective and retrospective comparative study. Materials and Methods: The medical charts of 782 women who had given birth to low-weight babies in 2013 and 2014 were reviewed retrospectively. The prospective part of the study involved measuring serum levels of VEGF in 150 pregnant women: 50 women with growthrestricted fetuses (Group I), 50 women with low-weight fetuses without hemodynamic disruptions or placental abnormalities (Group II), and 50 women with healthy pregnancies (Group III). Based on the babies’ gestational term at birth, the women in each group were divided into two subgroups: between 22 weeks and 0 days and 31 weeks and 6 days (subgroup 1) and ≥32 weeks and 0 days (subgroup 2). The data obtained were processed using descriptive statistics and compared with data obtained through other fetal assessments. Study Results: The pregnant women with growth-restricted fetuses had higher VEGF levels by a statistically significant margin (p<0.00001) than the women in groups II and III: median levels were 310 (Q1–Q3: 270–508), 33 (Q1–Q3: 31–38), and 36 (Q1–Q3: 32–40) pg/mL, respectively, in subgroups 1 and 174 (Q1–Q3: 100–214), 78 (Q1–Q3: 73–86), and 82 (Q1–Q3: 78–88) pg/mL, respectively, in subgroups 2. VEGF levels ≥100 pg/mL were associated with fetal growth restriction (FGR) (p = 0.0001) and levels ≥200 pg/mL with a high risk of antenatal fetal death (p = 0.026) or early neonatal death (p = 0.03). Conclusion: For women with growth-restricted fetuses, VEGF serum levels ≥200 pg/mL are an additional risk factor for unfavorable perinatal outcomes, which helps to optimize obstetrical management for these patients. Keywords: low-weight fetus, fetal growth retardation, vascular endothelial growth factor.

scholarly journals Excess Soluble fms-like Tyrosine Kinase 1 Correlates With Endothelial Dysfunction and Organ Failure in Critically Ill Coronavirus Disease 2019 Patients

2020 ◽  
Author(s):  
Vincent Dupont ◽  
Lukshe Kanagaratnam ◽  
Antoine Goury ◽  
Gaël Poitevin ◽  
Mathieu Bard ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Clinical Trials ◽  
Growth Factor ◽  
Endothelial Dysfunction ◽  
Tyrosine Kinase ◽  
Organ Failure ◽  
Symptom Severity ◽  
Plasma Levels ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Abstract Excess soluble fms-like tyrosine kinase 1 (sFlt-1), a soluble inhibitor of vascular endothelial growth factor pathway, has been demonstrated to promote endothelial dysfunction. Here, we demonstrate that sFlt-1 plasma levels correlate with respiratory symptom severity, expression of endothelial dysfunction biomarker, and incidence of organ failure in coronavirus disease 2019 patients. Clinical Trials Registration NCT04394195.

Sign in / Sign up

Export Citation Format

Share Document